Article citationsMore>>

Lin, T.L., Wang, Q.H., Brown, P., Peacock, C., Merchant, A.A., Brennan, S., Jones, E., McGovern, K., Watkins, D.N. and Sakamoto, K.M. (2010) Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926. PLOS ONE, 5, e15262.
https://doi.org/10.1371/journal.pone.0015262

has been cited by the following article:

• TITLE: Transforming Growth Factor and the Role of Epigenetic Aberrancies in Oncogenic Amplifications: A New Perspective in Preventive and Therapeutic Arena

  AUTHORS: M. Nezami, S. Hager, R. Shirazi

  KEYWORDS: Tumor Onco-Promotor, Gene Mutations, Gene Amplifications, Epigenetics Multi Targeted Epigenetic Therapies

  JOURNAL NAME: Journal of Cancer Therapy, Vol.14 No.9, September 28, 2023

  ABSTRACT: Three genetic mechanisms activate oncogenes in human neoplasms: 1) mutations, 2) gene amplification, and 3) chromosome rearrangements. These mechanisms result in either an alteration of protooncogene structure or an increase in protooncogene expression. The role of epigenetic aberrancies in carcinogenesis has been described earlier however to clinicians, the biological implications of epigenetic therapies to prevent cancer and the mechanisms involved have been a mystery. Furthermore, there is no biomarker suggested to track the carcinogenesis steps long before cancer develops, and this has caused a significant lack of proactive and preventive measures to be taken as all recommendations in preventive oncology are either deficiently and blindly made or through screening methods which are too late in the game. Here we explored a very different approach by applying our deepest understanding of epigenetics and carcinogenesis and even further we developed a framework where our clinical findings could translate to the research and vice versa by generating advanced and novel hypotheses on “how we get cancer”, by exploring the relation between the host and the tumor cells in a way no one had perceived before. The role of specific cancer stem cell pathways is dissected and how to inhibit each of these initiators using multitargeted epigenetic therapies and off-label medications are explained. We should admit that without considering this sophisticated amazing biological network, cancer will remain an unsolved challenge. Further, we were able to solve this unsolved puzzle by bridging the gap from a hypothetical point of view/hypothesis to possibilities that explain the clinical findings we had observed, and conclude that such an approach can completely change the way practitioners are treating cancer.